Rituximab therapy effective for ANCA-associated vasculitis
Phys.Org
In an article published today in the New England Journal of Medicine, Immune Tolerance Network (ITN) researchers demonstrated that a single course of rituximab therapy (anti-CD20; Rituxan, Genentech, Inc.) is as effective as the current standard of ...
NIH-funded study finds that rituximab is as effective as standard therapy for ...News-Medical.net
Keeping Vasculitis at BaydailyRx
Rituxan Helps in Vasculitis Over Long TermMedPage Today

all 5 news articles »